Copenhagen, Denmark, January 14, 2015 – Bifodan A/S, the Danish based, – specialized provider of innovative probiotic solutions, – announces the establishment of a separate Business Unit for its Ecovag® probiotic activities targeting women’s intimate health.
“Bifodan enjoys a solid position of this segment and by organizing our activities in a Business Unit structure, we create the best possible framework for further development of this area” says CEO, Steen Andersen. “We have appointed Niels Peter Bak, formerly VP of Marketing & Business Development at Bifodan, to head up the new Business Unit.”
“Probiotics for women’s intimate health is one of the fastest growing new segments of the overall probiotic market, in part driven by mounting scientific evidence in support of vaginal application of probiotics. Featuring patented and researched probiotic strains, innovative, products with proven clinical efficacy and a strong commercial track record, Ecovag® is possibly the “best in class” B2B technology platform in this area, explains Niels Peter Bak.”
“The overall strategy of the new Business Unit is to reinforce our B2B leadership position for probiotics targeting women’s intimate health. Through existing and new partnerships, we seek to expand the geographical reach of our activities. In addition, the efficacy of our products is being further substantiated through additional clinical trials in close collaboration with our international scientific network and business partners”, concludes Niels Peter Bak.